Welcome to our dedicated page for BiondVax Pharmaceuticals Ltd. news (Ticker: bvxv), a resource for investors and traders seeking the latest updates and insights on BiondVax Pharmaceuticals Ltd. stock.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company pioneering innovative solutions in the realm of inflammation and immunology (I&I). With a robust pipeline of nanosized VHH antibodies known as NanoAbs, BiondVax is targeting diseases with significant unmet medical needs. The company has made notable strides, particularly with its leading product, an intradermal NanoAb targeting IL-17 for treating mild to moderate plaque psoriasis. This product has shown promising results in preclinical ex-vivo trials and is gearing up for human clinical trials in 2025.
BiondVax operates two main business units. The first focuses on the in-house development of biological therapeutic products, leveraging its NanoAb technology licensed from the Max Planck Society and the University Medical Center Göttingen, Germany. The second unit, Scinai Bioservices, is a boutique Contract Development and Manufacturing Organization (CDMO) that offers end-to-end services ranging from drug development to GMP manufacturing. Launched in Q3 2023, Scinai Bioservices has already secured contracts with several biotechnology companies and aims to support small biotech firms in bringing their products to market efficiently.
The company recently welcomed Liat Halpert as Head of Business Development and Sales. Halpert, with her extensive experience from Novartis, is expected to expand Scinai’s CDMO business, particularly targeting European and U.S.-based biotech companies. This strategic move is anticipated to significantly boost BiondVax's revenue and establish it as a key partner for small biotechnology firms.
In recent news, BiondVax announced successful preclinical results of its IL-17 targeting NanoAb for psoriasis treatment. Additionally, its NanoAbs for COVID-19 have shown efficacy in preclinical trials, demonstrating potential in preventing and treating viral respiratory diseases through inhalation, a convenient administration route.
BiondVax's financial stability and strategic partnerships position it well for future growth. The company continues to seek collaborative opportunities with mid and large-cap pharmaceutical companies to advance its NanoAb therapies through clinical trials and towards commercialization.
For the latest updates and detailed information, visit BiondVax’s official website at www.biondvax.com.
FAQ
What does BiondVax Pharmaceuticals Ltd. do?
What are NanoAbs?
What recent achievements has BiondVax made?
Who is Liat Halpert?
What services does Scinai Bioservices offer?
When are human clinical trials for the psoriasis NanoAb expected?
What are the potential applications of BiondVax's NanoAbs?
How is BiondVax planning to expand its CDMO business?
What regulatory approvals does BiondVax need?
Where can I find more information about BiondVax Pharmaceuticals Ltd.?
